GAMMA Investing LLC Purchases Shares of 9,810 Adaptive Biotechnologies Co. (NASDAQ:ADPT)

GAMMA Investing LLC purchased a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 9,810 shares of the company’s stock, valued at approximately $59,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ADPT. Millennium Management LLC grew its holdings in shares of Adaptive Biotechnologies by 1,008.3% in the second quarter. Millennium Management LLC now owns 9,262,341 shares of the company’s stock worth $33,530,000 after purchasing an additional 8,426,580 shares during the last quarter. Rubric Capital Management LP raised its holdings in shares of Adaptive Biotechnologies by 33.3% during the second quarter. Rubric Capital Management LP now owns 14,000,000 shares of the company’s stock valued at $50,680,000 after acquiring an additional 3,500,000 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Adaptive Biotechnologies by 50.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,912,027 shares of the company’s stock worth $14,162,000 after acquiring an additional 1,319,709 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Adaptive Biotechnologies by 12.1% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,733,884 shares of the company’s stock valued at $39,597,000 after purchasing an additional 834,253 shares in the last quarter. Finally, Clearline Capital LP purchased a new position in shares of Adaptive Biotechnologies during the third quarter valued at about $3,147,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $6.50 on Monday. The company’s fifty day simple moving average is $6.01 and its 200-day simple moving average is $5.01. Adaptive Biotechnologies Co. has a 1-year low of $2.28 and a 1-year high of $7.46. The stock has a market capitalization of $959.26 million, a PE ratio of -4.85 and a beta of 1.47.

Analyst Ratings Changes

ADPT has been the subject of several research reports. Piper Sandler increased their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. BTIG Research lifted their price objective on Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.